Celcuity Inc. (CELC)

NCM – Real vaqt narxi. Valyuta: USD

124.68

-0.96 (-0.76%)

Yopilishda: May 12, 2026, 4:00 PM EDT

125.00

+0.32 (0.26%)

Bozor oldidan: May 13, 2026, 8:31 AM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Celcuity Inc. (CELC)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Celcuity Inc. (CELC)

Celcuity Schedules Release of First Quarter 2026 Financial Results and Webcast/Conference Call

Why Is Celcuity Stock Rallying Today?

Celcuity's Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free Survival in PIK3CA Mutant Cohort

Celcuity: Best-In-Class Potential With 2-3x Upside If Mutant Data Delivers

Why Celcuity Stock Popped Today

Celcuity Inc. (CELC) Q4 2025 Earnings Call Transcript

Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Videolar

No Data

Press-relizlar

Celcuity's Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free Survival in PIK3CA Mutant Cohort

Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Celcuity Announces Publication of Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Study of Gedatolisib Regimens in HR+/HER2- Advanced Breast Cancer in Journal of Clinical Oncology

Celcuity Appoints Charles Romp to its Board of Directors

Search stocks

Celcuity Inc. (CELC)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Celcuity Inc. (CELC)

Celcuity Schedules Release of First Quarter 2026 Financial Results and Webcast/Conference Call

Why Is Celcuity Stock Rallying Today?

Celcuity's Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free Survival in PIK3CA Mutant Cohort

Celcuity: Best-In-Class Potential With 2-3x Upside If Mutant Data Delivers

Why Celcuity Stock Popped Today

Celcuity Inc. (CELC) Q4 2025 Earnings Call Transcript

Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Videolar

No Data

Press-relizlar

Celcuity's Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free Survival in PIK3CA Mutant Cohort

Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Celcuity Announces Publication of Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Study of Gedatolisib Regimens in HR+/HER2- Advanced Breast Cancer in Journal of Clinical Oncology

Celcuity Appoints Charles Romp to its Board of Directors